Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943125 | 1.00 | FAP (0.44) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL27421382 | 0.95 | FAP (0.47) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL18911031 | 0.95 | FAP (0.44) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL23420078 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL14978852 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL20733059 | 0.95 | FAP (0.48) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL17722933 | 0.94 | FAP (0.44) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL18911020 | 0.94 | SIRT2 (0.40) | FAPSIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL23347003 | 0.93 | FAP (0.42) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL21659206 | 0.93 | FAP (0.42) | FAPMAP1LC3BSIRT5SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| WO-2020236792-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2017214456-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | FAP 25/4885MAP1LC3B 1942/4885SIRT5 678/4885 |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885SIRT5 2607/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | FAP 2388/4885MAP1LC3B 3281/4885SIRT5 4480/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | FAP 3499/4885MAP1LC3B 1900/4885SIRT5 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.